Pfizer And The Challenges Of The Global Pharmaceutical Industry
Download Pfizer And The Challenges Of The Global Pharmaceutical Industry full books in PDF, epub, and Kindle. Read online free Pfizer And The Challenges Of The Global Pharmaceutical Industry ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads.
Author |
: Axel Jörn |
Publisher |
: Anchor Academic Publishing |
Total Pages |
: 29 |
Release |
: 2016-02-05 |
ISBN-10 |
: 9783960675068 |
ISBN-13 |
: 3960675062 |
Rating |
: 4/5 (68 Downloads) |
Synopsis Pfizer and the Challenges of the Global Pharmaceutical Industry by : Axel Jörn
This Case Study defines the global pharmaceutical industry and its „boundaries“, analyses the profitability/attractiveness of the global pharmaceutical industry by using M.E.Porters’ Five-Forces-Model and answers the questions what overall industry trends can be identified and how the profitability/attractiveness of the industry will change in the future. Furthermore it explains and evaluates Pfizer’s new strategy and examines what Pfizer did in the recent years to maintain their profitability.
Author |
: Axel Jörn |
Publisher |
: Anchor Academic Publishing |
Total Pages |
: 33 |
Release |
: 2016-07 |
ISBN-10 |
: 9783960670063 |
ISBN-13 |
: 3960670060 |
Rating |
: 4/5 (63 Downloads) |
Synopsis Pfizer and the Challenges of the Global Pharmaceutical Industry by : Axel Jörn
This Case Study defines the global pharmaceutical industry and its „boundaries“, analyses the profitability/attractiveness of the global pharmaceutical industry by using M.E.Porters’ Five-Forces-Model and answers the questions what overall industry trends can be identified and how the profitability/attractiveness of the industry will change in the future. Furthermore, it explains and evaluates Pfizer’s new strategy and examines what Pfizer did in the recent years to maintain their profitability.
Author |
: Congressional Budget Office |
Publisher |
: Lulu.com |
Total Pages |
: 65 |
Release |
: 2013-06-09 |
ISBN-10 |
: 9781304121448 |
ISBN-13 |
: 1304121445 |
Rating |
: 4/5 (48 Downloads) |
Synopsis Research and Development in the Pharmaceutical Industry (A CBO Study) by : Congressional Budget Office
Perceptions that the pace of new-drug development has slowed and that the pharmaceutical industry is highly profitable have sparked concerns that significant problems loom for future drug development. This Congressional Budget Office (CBO) study-prepared at the request of the Senate Majority Leader-reviews basic facts about the drug industry's recent spending on research and development (R&D) and its output of new drugs. The study also examines issues relating to the costs of R&D, the federal government's role in pharmaceutical research, the performance of the pharmaceutical industry in developing innovative drugs, and the role of expected profits in private firms' decisions about investing in drug R&D. In keeping with CBO's mandate to provide objective, impartial analysis, the study makes no recommendations. David H. Austin prepared this report under the supervision of Joseph Kile and David Moore. Colin Baker provided valuable consultation...
Author |
: John L. LaMattina |
Publisher |
: John Wiley & Sons |
Total Pages |
: 173 |
Release |
: 2012-12-10 |
ISBN-10 |
: 9781118511251 |
ISBN-13 |
: 1118511255 |
Rating |
: 4/5 (51 Downloads) |
Synopsis Devalued and Distrusted by : John L. LaMattina
An expert's view on solving the challenges confronting today's pharmaceutical industry Author John LaMattina, a thirty-year veteran of the pharmaceutical industry and former president of Pfizer's Global R&D Division, is internationally recognized as an expert on the pharmaceutical industry. His first book, Drug Truths: Dispelling the Myths About Pharma R&D, was critically acclaimed for clearing up misconceptions about the pharmaceutical industry and providing an honest account of the contributions of pharmaceutical research and development to human health and well-being. As he toured the country discussing Drug Truths, Dr. LaMattina regularly came across people who were filled with anger, accusing the pharmaceutical industry of making up diseases, hiding dangerous side effects, and more. This book was written in response to that experience, critically examining public perceptions and industry realities. Starting with "4 Secrets that Drug Companies Don't Want You to Know," Devalued and Distrusted provides a fact-based account of how the pharmaceutical industry works and the challenges it faces. It addresses such critical issues as: Why pharmaceutical R&D productivity has declined Where pharmaceutical companies need to invest their resources What can be done to solve core health challenges, including cancer, diabetes, and neurodegenerative diseases How the pharmaceutical industry can regain public trust and resuscitate its image Our understanding of human health and disease grows daily; however, converting science into medicine is increasingly challenging. Reading Devalued and Distrusted, you'll not only gain a greater appreciation of those challenges, but also the role that the pharmaceutical industry currently plays and can play in solving those challenges. Get to know the author: Read an interview with John LaMattina or watch a video on ChemistryViews! Interview: John LaMattina: 30 Years in Pharma Video: Can the Pharmaceutical Industry Restory its Broken Image?
Author |
: Ellen F. M. 't Hoen |
Publisher |
: |
Total Pages |
: 136 |
Release |
: 2009 |
ISBN-10 |
: 9079700061 |
ISBN-13 |
: 9789079700066 |
Rating |
: 4/5 (61 Downloads) |
Synopsis The Global Politics of Pharmaceutical Monopoly Power by : Ellen F. M. 't Hoen
In The Global Politics of Pharmaceutical Monopoly Power, researcher and global advocate Ellen 't Hoen explains how new global rules for pharmaceutical patenting impact access to medicines in the developing world. The book gives an account of the current debates on intellectual property, access to medicines, and medical innovation, and provides historical context that explains how the current system emerged. This book supports major policy changes in the management of pharmaceutical patents and the way medical innovation is financed in order to protect public health and, in particular, promote access to essential medicines for all. The Open Society Institute provided support to translate this report into Russian.
Author |
: Institute of Medicine |
Publisher |
: National Academies Press |
Total Pages |
: 225 |
Release |
: 1991-02-01 |
ISBN-10 |
: 9780309044912 |
ISBN-13 |
: 030904491X |
Rating |
: 4/5 (12 Downloads) |
Synopsis The Changing Economics of Medical Technology by : Institute of Medicine
Americans praise medical technology for saving lives and improving health. Yet, new technology is often cited as a key factor in skyrocketing medical costs. This volume, second in the Medical Innovation at the Crossroads series, examines how economic incentives for innovation are changing and what that means for the future of health care. Up-to-date with a wide variety of examples and case studies, this book explores how payment, patent, and regulatory policiesâ€"as well as the involvement of numerous government agenciesâ€"affect the introduction and use of new pharmaceuticals, medical devices, and surgical procedures. The volume also includes detailed comparisons of policies and patterns of technological innovation in Western Europe and Japan. This fact-filled and practical book will be of interest to economists, policymakers, health administrators, health care practitioners, and the concerned public.
Author |
: Great Britain: Parliament: House of Commons: Health Committee |
Publisher |
: The Stationery Office |
Total Pages |
: 556 |
Release |
: 2005-04-26 |
ISBN-10 |
: 0215024575 |
ISBN-13 |
: 9780215024572 |
Rating |
: 4/5 (75 Downloads) |
Synopsis The Influence of the Pharmaceutical Industry by : Great Britain: Parliament: House of Commons: Health Committee
Incorporating HC 1030-i to iii.
Author |
: Kung-Chung Liu |
Publisher |
: Springer Nature |
Total Pages |
: 513 |
Release |
: 2019-09-06 |
ISBN-10 |
: 9789811381027 |
ISBN-13 |
: 981138102X |
Rating |
: 4/5 (27 Downloads) |
Synopsis Innovation, Economic Development, and Intellectual Property in India and China by : Kung-Chung Liu
This open access book analyses intellectual property codification and innovation governance in the development of six key industries in India and China. These industries are reflective of the innovation and economic development of the two economies, or of vital importance to them: the IT Industry; the film industry; the pharmaceutical industry; plant varieties and food security; the automobile industry; and peer production and the sharing economy. The analysis extends beyond the domain of IP law, and includes economics and policy analysis. The overarching concern that cuts through all chapters is an inquiry into why certain industries have developed in one country and not in the other, including: the role that state innovation policy and/or IP policy played in such development; the nature of the state innovation policy/IP policy; and whether such policy has been causal, facilitating, crippling, co-relational, or simply irrelevant. The book asks what India and China can learn from each other, and whether there is any possibility of synergy. The book provides a real-life understanding of how IP laws interact with innovation and economic development in the six selected economic sectors in China and India. The reader can also draw lessons from the success or failure of these sectors.
Author |
: |
Publisher |
: U.S. Government Printing Office |
Total Pages |
: 94 |
Release |
: 1998 |
ISBN-10 |
: PURD:32754071785707 |
ISBN-13 |
: |
Rating |
: 4/5 (07 Downloads) |
Synopsis How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry by :
Author |
: Ed Schoonveld |
Publisher |
: Gower Publishing, Ltd. |
Total Pages |
: 384 |
Release |
: 2011 |
ISBN-10 |
: 1409420523 |
ISBN-13 |
: 9781409420521 |
Rating |
: 4/5 (23 Downloads) |
Synopsis The Price of Global Health by : Ed Schoonveld
The Price of Global Health is the first book of its kind: an in-depth but straightforward exploration of the pharmaceutical pricing strategy process, its underlying market access, general business and ethical considerations, and its implications for payers, physicians and patients. It is a much needed and invaluable resource for anybody interested, involved in or affected by the development, funding and use of prescription drugs. In particular, it is of critical importance to pharmaceutical company executives and other leaders and professionals in commercialization and drug development, including marketing, business development, market access and pricing, clinical development, drug discovery, regulatory affairs, health outcomes, market research and public affairs.